Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07209215 · ClinicalTrials.gov registry record · Phase 2
ctDNA-Informed Management of Early-Stage Rectal Cancer
A Phase 2 study, sponsored by University of California, Davis.
- Not yet
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT07209215: Clinical Trial Phase 2 study, sponsored by University of California, Davis.
NCT07209215 is a Phase 2 study that has not yet begun recruiting, run by University of California, Davis. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07209215, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, Davis.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
This is a phase 2 pragmatic study to examine the utility of ctDNA-informed treatment management for participants with early-stage rectal cancer using the Signatera Genome assay. The primary aims are to 1) assess pathologic complete response (path CR) in the ctDNA informed management arm; 2) assess pathologic complete response (path CR) in the post total neoadjuvant therapy (TNT) standard of care (SOC) surgery arm; and 3) assess disease free survival (DFS) in the ctDNA informed management arm.
Primary Outcome
Percent of participants with local regrowth within 2 years of total neoadjuvant therapy (TNT)
Interventions
- DRUG Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-03 |
| Est. Completion | 2028-05 |
| Phase | Phase 2 |
What is known before NCT07209215 opens enrollment
NCT07209215 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 1 intervention - of which Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT) is the first listed.
NCT07209215 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07209215 about?
NCT07209215 is a clinical study titled "ctDNA-Informed Management of Early-Stage Rectal Cancer". This is a phase 2 pragmatic study to examine the utility of ctDNA-informed treatment management for participants with early-stage rectal cancer using the Signatera Genome assay. The primary aims are to 1) assess pathologic complete response (path CR) in the ctDNA informed management arm; 2) assess p...
What is the current status of trial NCT07209215?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2026-03. Estimated completion is 2028-05.
What interventions are being tested in trial NCT07209215?
The interventions under investigation include: Signatera Genome ultra-sensitive ctDNA blood test + total neoadjuvant therapy (TNT) (DRUG).
Who is sponsoring clinical trial NCT07209215?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07209215's enrollment target sits among peer trials
200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia